Shattuck Labs (STTK) risk factors

49 risks, 3 new, 5 dropped, 11 reworded since the prior year. Shattuck advanced lead candidate SL-325 into Phase 1 trials while expanding net operating loss carryforwards to $251 million.

51 risks. Shattuck Labs is a preclinical biotechnology company with a net loss of $75.4 million in 2024 and an accumulated deficit of $381.7 million. The business is heavily dependent on the clinical success and patent protection of its lead product candidate, SL-325, for inflammatory bowel disease. Operations face substantial dilution risks from equity raises, heavy reliance on third-party manufacturers, and complex intellectual property challenges.